RxDoctor Payments Data

Melida Tellez, MD

Family Medicine · Sugar Land, TXNPI 1528296084

Payments from drug & device makers

$1,681in general payments, 2019–2025

Across 87 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$489
  • Abbott$245
  • Lilly USA, LLC$188
  • Pfizer$185
  • AbbVie$104
  • GSK$94
  • plus $377 from 8 others

What the payments were for

  • Food & beverage$1,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk26$489
Abbott12$245
Lilly USA, LLC9$188
Pfizer10$185
AbbVie5$104
GSK6$94
Merck5$85
Amgen(2 entities)4$78
Sanofi Pasteur Inc.2$64
Biohaven Pharmaceutical Holding Company Ltd.3$51
AstraZeneca2$36
Avvisto Therapeutics, LLC1$24
Astellas Pharma US Inc1$23
Exact Sciences1$16

How this compares

$1,681 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,557
Medicare patients
159
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$54,542
JanuviaSitagliptin Phosphate31$27,553
EliquisApixaban28$21,677
MounjaroTirzepatide14$17,178
FarxigaDapagliflozin Propanediol13$12,289
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,173
SynthroidLevothyroxine Sodium42$4,249
Doxepin Hcl22$3,169
Losartan Potassium226$2,520
Atorvastatin Calcium211$2,121
Levothyroxine Sodium201$2,085
Rosuvastatin Calcium134$2,080
Albuterol Sulfate HfaAlbuterol Sulfate68$1,797
Simvastatin108$1,267
Metformin Hcl ErMetformin Hcl115$1,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$489$54,54254 claims
MerckJanuvia$85$27,55331 claims
PfizerEliquis$185$21,67728 claims
Lilly USA, LLCMounjaro$188$17,17814 claims
AstraZenecaFarxiga$36$12,28913 claims
GSKTrelegy Ellipta$94$10,17312 claims
AbbVieSynthroid$104$4,24942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →